EXEL
HealthcareExelixis, Inc.
Prev Close
$41.17
Open
$41.66
High
$41.74
Low
$40.55
Volume
1.41M
Market Cap
$11.21B
P/E
18.02
Div Yield
—
Over the past 12 months, insider activity at Exelixis, Inc. (EXEL) has been dominated by selling, with 1 insider purchase totaling $1.19M and 34 insider sales totaling $97.03M. The most recent insider transaction was by Aftab Dana (officer: EVP, Research and Development), who sold $2.13M worth of shares on Feb 26, 2026. Exelixis, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $11.21B.
Buys (12M)
1
$1.19M
Sells (12M)
34
$97.03M
Net Activity
Net Seller
$95.84M
Active Insiders
16
last 12 mo
EXEL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026↗ | Aftab Dana | officer: EVP, Research and Development | Sell | 47,918 | $44.50 | $2.13M | 616,106 |
| Feb 23, 2026↗ | Aftab Dana | officer: EVP, Research and Development | Sell | 29,873 | $44.35 | $1.32M | 664,024 |
| Feb 20, 2026↗ | WYSZOMIERSKI JACK L | director | Sell | 99,574 | $44.01 | $4.38M | 279,942 |
| Feb 19, 2026↗ | Aftab Dana | EVP, Research and Development | Sell | 29,873 | $44.35 | $1.32M | 0 |
| Feb 19, 2026↗ | Smith Julie | director | Sell | 106,539 | $44.00 | $4.69M | 20,590 |
| Feb 18, 2026↗ | Eckhardt Sue Gail | director | Sell | 3,856 | $43.79 | $168.9K | 17,524 |
| Feb 18, 2026↗ | Haley Patrick J. | officer: EVP, Commercial | Sell | 67,814 | $43.52 | $2.95M | 446,686 |
| Feb 18, 2026↗ | Hefti Brenda | officer: SVP and General Counsel | Sell | 18,669 | $44.01 | $821.6K | 96,512 |
| Feb 18, 2026↗ | MORRISSEY MICHAEL | President and CEO | Sell | 489,996 | $43.92 | $21.52M | 0 |
| Feb 18, 2026↗ | Oliver Bob | director | Sell | 30,250 | $43.81 | $1.33M | 42,282 |
| Feb 18, 2026↗ | Senner Christopher J. | officer: EVP and CFO | Sell | 64,895 | $43.32 | $2.81M | 1,042,580 |
| Feb 18, 2026↗ | WYSZOMIERSKI JACK L | Director | Sell | 99,574 | $44.01 | $4.38M | 0 |
| Feb 17, 2026↗ | Smith Julie | Director | Sell | 106,539 | $44.00 | $4.69M | 0 |
| Feb 15, 2026↗ | Aftab Dana | EVP, Research and Development | Sell | 39,205 | $43.92 | $1.72M | 0 |
| Feb 15, 2026↗ | Haley Patrick J. | EVP, Commercial | Sell | 99,297 | $43.64 | $4.33M | 0 |
| Feb 15, 2026↗ | Hefti Brenda | SVP and General Counsel | Sell | 24,099 | $43.99 | $1.06M | 0 |
| Feb 13, 2026↗ | Eckhardt Sue Gail | Director | Sell | 3,856 | $43.79 | $168.9K | 0 |
| Feb 13, 2026↗ | Oliver Bob | Director | Sell | 30,250 | $43.81 | $1.33M | 0 |
| Feb 13, 2026↗ | Senner Christopher J. | EVP and CFO | Sell | 100,765 | $43.53 | $4.39M | 0 |
| Nov 26, 2025↗ | JOHNSON DAVID EDWARD | Director | Buy | 27,532 | $43.12 | $1.19M | 1,553,260 |
| Nov 24, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 72,230 | $42.18 | $3.05M | 402,072 |
| Nov 13, 2025↗ | Aftab Dana | EVP, Research and Development | Sell | 48,383 | $42.50 | $2.06M | 664,778 |
| Nov 13, 2025↗ | Beckerle Mary C | Director | Sell | 24,622 | $41.93 | $1.03M | 40,218 |
| Nov 13, 2025↗ | PAPADOPOULOS STELIOS | Director | Sell | 100,000 | $43.55 | $4.36M | 1,189,230 |
| Jun 4, 2025↗ | Eckhardt Sue Gail | Director | Sell | 18,838 | $42.74 | $805.1K | 21,384 |
| Jun 4, 2025↗ | WYSZOMIERSKI JACK L | Director | Sell | 7,535 | $43.09 | $324.7K | 358,882 |
| May 22, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 34,387 | $44.06 | $1.52M | 412,072 |
| May 22, 2025↗ | Heyman Tomas J. | Director | Sell | 4,544 | $44.29 | $201.3K | 32,470 |
| May 16, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 136,383 | $47.58 | $6.49M | 491,164 |
| May 16, 2025↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $46.18 | $1.15M | 693,396 |
| May 16, 2025↗ | PAPADOPOULOS STELIOS | Director | Sell | 36,508 | $44.35 | $1.62M | 1,279,420 |
| May 16, 2025↗ | Peterson Amy C. | EVP Prod Dev & Med Aff & CMO | Sell | 72,776 | $45.47 | $3.31M | 465,393 |
| May 16, 2025↗ | POSTE GEORGE | Director | Sell | 20,634 | $45.99 | $949.0K | 169,020 |
| May 16, 2025↗ | Senner Christopher J. | EVP and CFO | Sell | 100,000 | $46.00 | $4.60M | 967,842 |
| May 5, 2025↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 1,508 | $39.00 | $58.8K | 693,181 |
| Mar 5, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 10,000 | $38.80 | $388.0K | 341,028 |
| Feb 28, 2025↗ | Smith Julie | Director | Sell | 73,808 | $38.00 | $2.80M | 10,778 |
| Feb 28, 2025↗ | WYSZOMIERSKI JACK L | Director | Sell | 8,768 | $37.80 | $331.4K | 356,605 |
| Feb 26, 2025↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 26,987 | $36.75 | $991.8K | 511,908 |
| Feb 26, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 52,636 | $36.98 | $1.95M | 303,310 |
| Feb 26, 2025↗ | Oliver Bob | Director | Sell | 18,647 | $37.25 | $694.6K | 33,514 |
| Feb 26, 2025↗ | Senner Christopher J. | EVP and CFO | Sell | 29,314 | $36.14 | $1.06M | 779,607 |
| Feb 19, 2025↗ | Beckerle Mary C | Director | Sell | 12,210 | $34.88 | $425.9K | 34,262 |
| Feb 19, 2025↗ | Eckhardt Sue Gail | Director | Sell | 11,568 | $35.02 | $405.1K | 34,262 |
| Feb 19, 2025↗ | Freire Maria C | Director | Sell | 44,114 | $34.94 | $1.54M | 91,007 |
| Feb 19, 2025↗ | POSTE GEORGE | Director | Sell | 15,874 | $34.74 | $551.5K | 169,020 |
| Dec 2, 2024↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 60,000 | $36.67 | $2.20M | 486,059 |
| Nov 26, 2024↗ | Haley Patrick J. | EVP, Commercial | Sell | 10,000 | $35.27 | $352.7K | 278,665 |
| Nov 19, 2024↗ | Haley Patrick J. | EVP, Commercial | Sell | 41,588 | $34.36 | $1.43M | 308,046 |
| Nov 7, 2024↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 96,986 | $35.00 | $3.39M | 498,945 |
| Nov 5, 2024↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 50,000 | $34.13 | $1.71M | 530,325 |
| Nov 5, 2024↗ | POSTE GEORGE | Director | Sell | 30,000 | $34.00 | $1.02M | 169,020 |
| Nov 1, 2024↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 1,162 | $31.40 | $36.5K | 498,945 |
| Oct 30, 2024↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $28.39 | $709.8K | 580,325 |
| Sep 25, 2024↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $26.38 | $659.5K | 605,325 |
| Aug 28, 2024↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 20,000 | $25.79 | $515.8K | 630,325 |
| Aug 16, 2024↗ | Freire Maria C | Director | Sell | 8,250 | $26.56 | $219.1K | 91,007 |
| Aug 14, 2024↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 20,883 | $27.06 | $565.1K | 500,107 |
| Aug 12, 2024↗ | POSTE GEORGE | Director | Sell | 33,725 | $26.89 | $906.9K | 199,020 |
| Aug 9, 2024↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 95,000 | $25.00 | $2.38M | 520,990 |
| Aug 9, 2024↗ | Haley Patrick J. | EVP, Commercial | Sell | 14,000 | $25.50 | $357.0K | 341,036 |
| Aug 9, 2024↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 80,000 | $25.97 | $2.08M | 630,325 |
| Aug 9, 2024↗ | Senner Christopher J. | EVP and CFO | Sell | 125,000 | $27.19 | $3.40M | 721,680 |
| Jun 6, 2024↗ | WYSZOMIERSKI JACK L | Director | Sell | 8,287 | $22.00 | $182.3K | 349,499 |
| May 30, 2024↗ | JOHNSON DAVID EDWARD | Director | Buy | 425,000 | $20.55 | $8.73M | 1,525,730 |
| May 23, 2024↗ | Smith Julie | Director | Sell | 27,280 | $21.12 | $576.2K | 5,445 |
| May 22, 2024↗ | PAPADOPOULOS STELIOS | Director | Sell | 11,437 | $21.00 | $240.2K | 1,260,580 |
| May 22, 2024↗ | POSTE GEORGE | Director | Sell | 11,686 | $20.96 | $244.9K | 213,907 |
| May 15, 2024↗ | WYSZOMIERSKI JACK L | Director | Sell | 10,923 | $21.37 | $233.4K | 338,948 |
| Mar 25, 2024↗ | Garber Alan M | Director | Sell | 19,205 | $24.01 | $461.1K | 35,703 |
| Feb 27, 2024↗ | Haley Patrick J. | EVP, Commercial | Sell | 47,020 | $21.45 | $1.01M | 384,866 |
| Feb 22, 2024↗ | JOHNSON DAVID EDWARD | Director | Buy | 190,000 | $20.70 | $3.93M | 1,100,730 |
| Dec 14, 2023↗ | Haley Patrick J. | EVP, Commercial | Sell | 64,149 | $23.16 | $1.49M | 307,687 |
| Dec 14, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 25,000 | $23.01 | $575.3K | 533,345 |
| Dec 4, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 50,000 | $22.04 | $1.10M | 583,345 |
| Nov 29, 2023↗ | JOHNSON DAVID EDWARD | Director | Buy | 120,409 | $21.61 | $2.60M | 910,730 |
| Nov 29, 2023↗ | JOHNSON DAVID EDWARD | Director | Sell | 120,409 | $21.61 | $2.60M | 790,321 |
| Sep 1, 2023↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 4,600 | $22.47 | $103.4K | 399,943 |
| Aug 7, 2023↗ | Haley Patrick J. | EVP, Commercial | Sell | 30,553 | $20.67 | $631.5K | 285,467 |
| Aug 7, 2023↗ | Senner Christopher J. | EVP and CFO | Sell | 120,000 | $20.60 | $2.47M | 571,631 |
| Aug 3, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 55,710 | $19.63 | $1.09M | 571,976 |
| Apr 5, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 38,930 | $20.01 | $779.0K | 582,435 |
| Mar 14, 2023↗ | WYSZOMIERSKI JACK L | Director | Sell | 15,300 | $16.61 | $254.1K | 317,467 |
| Mar 3, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 77,860 | $17.13 | $1.33M | 527,716 |
| Mar 1, 2023↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 82,500 | $17.50 | $1.44M | 351,472 |
| Feb 23, 2023↗ | Garber Alan M | Director | Sell | 40,000 | $17.49 | $699.6K | 31,417 |
| Feb 10, 2023↗ | FELDBAUM CARL B | Director | Sell | 40,000 | $17.78 | $711.2K | 18,701 |
| Feb 8, 2023↗ | Haley Patrick J. | EVP, Commercial | Sell | 25,000 | $17.37 | $434.3K | 254,414 |
| Dec 16, 2022↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 20,000 | $15.88 | $317.6K | 410,958 |
| Dec 1, 2022↗ | POSTE GEORGE | Director | Sell | 40,000 | $16.68 | $667.2K | 193,189 |
| Nov 17, 2022↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 36,000 | $22.73 | $818.3K | 604,822 |
| Sep 14, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 40,000 | $17.94 | $717.6K | 261,591 |
| Jun 1, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 18,812 | $18.21 | $342.6K | 239,818 |
| May 13, 2022↗ | WILLSEY LANCE | Director | Sell | 40,000 | $19.65 | $786.0K | 424,415 |
| Apr 6, 2022↗ | WYSZOMIERSKI JACK L | Director | Sell | 6,696 | $23.00 | $154.0K | 273,192 |
| Apr 4, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 20,000 | $22.72 | $454.3K | 269,191 |
| Mar 30, 2022↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 18,000 | $22.00 | $396.0K | 618,519 |
| Mar 3, 2022↗ | Garber Alan M | Director | Sell | 21,301 | $21.00 | $447.3K | 31,417 |
| Feb 28, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 31,238 | $19.53 | $610.1K | 198,476 |
| Feb 28, 2022↗ | Hessekiel Jeffrey | EVP and General Counsel | Sell | 18,000 | $20.00 | $360.0K | 555,361 |
| Feb 24, 2022↗ | FELDBAUM CARL B | Director | Sell | 20,000 | $19.49 | $389.8K | 8,521 |
| Feb 24, 2022↗ | PAPADOPOULOS STELIOS | Director | Sell | 84,515 | $19.56 | $1.65M | 1,220,040 |
| Feb 4, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 60,000 | $17.91 | $1.07M | 245,241 |
| Dec 17, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 47,500 | $17.44 | $828.4K | 363,172 |
| Nov 26, 2021↗ | Haley Patrick J. | EVP, Commercial | Sell | 17,236 | $17.25 | $297.3K | 237,802 |
| Nov 23, 2021↗ | FELDBAUM CARL B | Director | Sell | 20,000 | $17.62 | $352.4K | 8,521 |
| Nov 17, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 47,500 | $18.09 | $859.3K | 411,240 |
| Nov 3, 2021↗ | Hessekiel Jeffrey | EVP and General Counsel | Sell | 5,117 | $22.03 | $112.7K | 632,825 |
| Oct 15, 2021↗ | Hessekiel Jeffrey | EVP and General Counsel | Sell | 12,883 | $22.02 | $283.7K | 637,942 |
| Oct 15, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 47,500 | $21.92 | $1.04M | 411,240 |
| Sep 17, 2021↗ | Haley Patrick J. | EVP, Commercial | Sell | 25,000 | $20.36 | $509.0K | 280,994 |
| Sep 17, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 47,500 | $20.46 | $971.9K | 389,467 |
| Aug 18, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 55,000 | $18.44 | $1.01M | 389,467 |
| Jul 16, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 60,000 | $17.47 | $1.05M | 389,467 |
| Jun 22, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 60,000 | $22.18 | $1.33M | 389,467 |
| May 18, 2021↗ | Haley Patrick J. | EVP, Commercial | Sell | 14,593 | $24.73 | $360.9K | 280,994 |
| May 17, 2021↗ | Freire Maria C | Director | Sell | 8,275 | $25.01 | $207.0K | 31,827 |
| May 17, 2021↗ | MARCHESI VINCENT T | Director | Sell | 40,000 | $25.04 | $1.00M | 66,115 |
| May 17, 2021↗ | POSTE GEORGE | Director | Sell | 40,802 | $24.97 | $1.02M | 157,190 |
| May 14, 2021↗ | Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | Sell | 100,000 | $25.38 | $2.54M | 614,078 |
| May 13, 2021↗ | PAPADOPOULOS STELIOS | Director | Sell | 20,770 | $24.98 | $518.8K | 1,288,130 |
| Apr 28, 2021↗ | Haley Patrick J. | EVP, Commercial | Sell | 7,665 | $25.03 | $191.9K | 297,392 |
| Apr 28, 2021↗ | Hessekiel Jeffrey | EVP and General Counsel | Sell | 18,000 | $25.03 | $450.5K | 628,248 |
| Apr 28, 2021↗ | Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | Sell | 50,000 | $25.00 | $1.25M | 613,482 |
| Apr 2, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 60,000 | $22.96 | $1.38M | 389,467 |
| Apr 2, 2021↗ | Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | Sell | 50,000 | $23.00 | $1.15M | 613,482 |
| Mar 31, 2021↗ | WYSZOMIERSKI JACK L | Director | Sell | 6,220 | $22.64 | $140.8K | 231,589 |
| Mar 17, 2021↗ | Garber Alan M | Director | Sell | 40,000 | $23.60 | $944.0K | 12,718 |
| Mar 3, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 65,000 | $22.11 | $1.44M | 340,072 |
EXEL Insider Buying Activity
The following table shows recent insider purchases of Exelixis, Inc. (EXEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 26, 2025↗ | JOHNSON DAVID EDWARD | Director | Buy | 27,532 | $43.12 | $1.19M | 1,553,260 |
| May 30, 2024↗ | JOHNSON DAVID EDWARD | Director | Buy | 425,000 | $20.55 | $8.73M | 1,525,730 |
| Feb 22, 2024↗ | JOHNSON DAVID EDWARD | Director | Buy | 190,000 | $20.70 | $3.93M | 1,100,730 |
| Nov 29, 2023↗ | JOHNSON DAVID EDWARD | Director | Buy | 120,409 | $21.61 | $2.60M | 910,730 |
EXEL Insider Selling Activity
The following table shows recent insider sales of Exelixis, Inc. (EXEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026↗ | Aftab Dana | officer: EVP, Research and Development | Sell | 47,918 | $44.50 | $2.13M | 616,106 |
| Feb 23, 2026↗ | Aftab Dana | officer: EVP, Research and Development | Sell | 29,873 | $44.35 | $1.32M | 664,024 |
| Feb 20, 2026↗ | WYSZOMIERSKI JACK L | director | Sell | 99,574 | $44.01 | $4.38M | 279,942 |
| Feb 19, 2026↗ | Aftab Dana | EVP, Research and Development | Sell | 29,873 | $44.35 | $1.32M | 0 |
| Feb 19, 2026↗ | Smith Julie | director | Sell | 106,539 | $44.00 | $4.69M | 20,590 |
| Feb 18, 2026↗ | Eckhardt Sue Gail | director | Sell | 3,856 | $43.79 | $168.9K | 17,524 |
| Feb 18, 2026↗ | Haley Patrick J. | officer: EVP, Commercial | Sell | 67,814 | $43.52 | $2.95M | 446,686 |
| Feb 18, 2026↗ | Hefti Brenda | officer: SVP and General Counsel | Sell | 18,669 | $44.01 | $821.6K | 96,512 |
| Feb 18, 2026↗ | MORRISSEY MICHAEL | President and CEO | Sell | 489,996 | $43.92 | $21.52M | 0 |
| Feb 18, 2026↗ | Oliver Bob | director | Sell | 30,250 | $43.81 | $1.33M | 42,282 |
| Feb 18, 2026↗ | Senner Christopher J. | officer: EVP and CFO | Sell | 64,895 | $43.32 | $2.81M | 1,042,580 |
| Feb 18, 2026↗ | WYSZOMIERSKI JACK L | Director | Sell | 99,574 | $44.01 | $4.38M | 0 |
| Feb 17, 2026↗ | Smith Julie | Director | Sell | 106,539 | $44.00 | $4.69M | 0 |
| Feb 15, 2026↗ | Aftab Dana | EVP, Research and Development | Sell | 39,205 | $43.92 | $1.72M | 0 |
| Feb 15, 2026↗ | Haley Patrick J. | EVP, Commercial | Sell | 99,297 | $43.64 | $4.33M | 0 |
| Feb 15, 2026↗ | Hefti Brenda | SVP and General Counsel | Sell | 24,099 | $43.99 | $1.06M | 0 |
| Feb 13, 2026↗ | Eckhardt Sue Gail | Director | Sell | 3,856 | $43.79 | $168.9K | 0 |
| Feb 13, 2026↗ | Oliver Bob | Director | Sell | 30,250 | $43.81 | $1.33M | 0 |
| Feb 13, 2026↗ | Senner Christopher J. | EVP and CFO | Sell | 100,765 | $43.53 | $4.39M | 0 |
| Nov 24, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 72,230 | $42.18 | $3.05M | 402,072 |
| Nov 13, 2025↗ | Aftab Dana | EVP, Research and Development | Sell | 48,383 | $42.50 | $2.06M | 664,778 |
| Nov 13, 2025↗ | Beckerle Mary C | Director | Sell | 24,622 | $41.93 | $1.03M | 40,218 |
| Nov 13, 2025↗ | PAPADOPOULOS STELIOS | Director | Sell | 100,000 | $43.55 | $4.36M | 1,189,230 |
| Jun 4, 2025↗ | Eckhardt Sue Gail | Director | Sell | 18,838 | $42.74 | $805.1K | 21,384 |
| Jun 4, 2025↗ | WYSZOMIERSKI JACK L | Director | Sell | 7,535 | $43.09 | $324.7K | 358,882 |
| May 22, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 34,387 | $44.06 | $1.52M | 412,072 |
| May 22, 2025↗ | Heyman Tomas J. | Director | Sell | 4,544 | $44.29 | $201.3K | 32,470 |
| May 16, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 136,383 | $47.58 | $6.49M | 491,164 |
| May 16, 2025↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $46.18 | $1.15M | 693,396 |
| May 16, 2025↗ | PAPADOPOULOS STELIOS | Director | Sell | 36,508 | $44.35 | $1.62M | 1,279,420 |
| May 16, 2025↗ | Peterson Amy C. | EVP Prod Dev & Med Aff & CMO | Sell | 72,776 | $45.47 | $3.31M | 465,393 |
| May 16, 2025↗ | POSTE GEORGE | Director | Sell | 20,634 | $45.99 | $949.0K | 169,020 |
| May 16, 2025↗ | Senner Christopher J. | EVP and CFO | Sell | 100,000 | $46.00 | $4.60M | 967,842 |
| May 5, 2025↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 1,508 | $39.00 | $58.8K | 693,181 |
| Mar 5, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 10,000 | $38.80 | $388.0K | 341,028 |
| Feb 28, 2025↗ | Smith Julie | Director | Sell | 73,808 | $38.00 | $2.80M | 10,778 |
| Feb 28, 2025↗ | WYSZOMIERSKI JACK L | Director | Sell | 8,768 | $37.80 | $331.4K | 356,605 |
| Feb 26, 2025↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 26,987 | $36.75 | $991.8K | 511,908 |
| Feb 26, 2025↗ | Haley Patrick J. | EVP, Commercial | Sell | 52,636 | $36.98 | $1.95M | 303,310 |
| Feb 26, 2025↗ | Oliver Bob | Director | Sell | 18,647 | $37.25 | $694.6K | 33,514 |
| Feb 26, 2025↗ | Senner Christopher J. | EVP and CFO | Sell | 29,314 | $36.14 | $1.06M | 779,607 |
| Feb 19, 2025↗ | Beckerle Mary C | Director | Sell | 12,210 | $34.88 | $425.9K | 34,262 |
| Feb 19, 2025↗ | Eckhardt Sue Gail | Director | Sell | 11,568 | $35.02 | $405.1K | 34,262 |
| Feb 19, 2025↗ | Freire Maria C | Director | Sell | 44,114 | $34.94 | $1.54M | 91,007 |
| Feb 19, 2025↗ | POSTE GEORGE | Director | Sell | 15,874 | $34.74 | $551.5K | 169,020 |
| Dec 2, 2024↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 60,000 | $36.67 | $2.20M | 486,059 |
| Nov 26, 2024↗ | Haley Patrick J. | EVP, Commercial | Sell | 10,000 | $35.27 | $352.7K | 278,665 |
| Nov 19, 2024↗ | Haley Patrick J. | EVP, Commercial | Sell | 41,588 | $34.36 | $1.43M | 308,046 |
| Nov 7, 2024↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 96,986 | $35.00 | $3.39M | 498,945 |
| Nov 5, 2024↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 50,000 | $34.13 | $1.71M | 530,325 |
| Nov 5, 2024↗ | POSTE GEORGE | Director | Sell | 30,000 | $34.00 | $1.02M | 169,020 |
| Nov 1, 2024↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 1,162 | $31.40 | $36.5K | 498,945 |
| Oct 30, 2024↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $28.39 | $709.8K | 580,325 |
| Sep 25, 2024↗ | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $26.38 | $659.5K | 605,325 |
| Aug 28, 2024↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 20,000 | $25.79 | $515.8K | 630,325 |
| Aug 16, 2024↗ | Freire Maria C | Director | Sell | 8,250 | $26.56 | $219.1K | 91,007 |
| Aug 14, 2024↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 20,883 | $27.06 | $565.1K | 500,107 |
| Aug 12, 2024↗ | POSTE GEORGE | Director | Sell | 33,725 | $26.89 | $906.9K | 199,020 |
| Aug 9, 2024↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 95,000 | $25.00 | $2.38M | 520,990 |
| Aug 9, 2024↗ | Haley Patrick J. | EVP, Commercial | Sell | 14,000 | $25.50 | $357.0K | 341,036 |
| Aug 9, 2024↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 80,000 | $25.97 | $2.08M | 630,325 |
| Aug 9, 2024↗ | Senner Christopher J. | EVP and CFO | Sell | 125,000 | $27.19 | $3.40M | 721,680 |
| Jun 6, 2024↗ | WYSZOMIERSKI JACK L | Director | Sell | 8,287 | $22.00 | $182.3K | 349,499 |
| May 23, 2024↗ | Smith Julie | Director | Sell | 27,280 | $21.12 | $576.2K | 5,445 |
| May 22, 2024↗ | PAPADOPOULOS STELIOS | Director | Sell | 11,437 | $21.00 | $240.2K | 1,260,580 |
| May 22, 2024↗ | POSTE GEORGE | Director | Sell | 11,686 | $20.96 | $244.9K | 213,907 |
| May 15, 2024↗ | WYSZOMIERSKI JACK L | Director | Sell | 10,923 | $21.37 | $233.4K | 338,948 |
| Mar 25, 2024↗ | Garber Alan M | Director | Sell | 19,205 | $24.01 | $461.1K | 35,703 |
| Feb 27, 2024↗ | Haley Patrick J. | EVP, Commercial | Sell | 47,020 | $21.45 | $1.01M | 384,866 |
| Dec 14, 2023↗ | Haley Patrick J. | EVP, Commercial | Sell | 64,149 | $23.16 | $1.49M | 307,687 |
| Dec 14, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 25,000 | $23.01 | $575.3K | 533,345 |
| Dec 4, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 50,000 | $22.04 | $1.10M | 583,345 |
| Nov 29, 2023↗ | JOHNSON DAVID EDWARD | Director | Sell | 120,409 | $21.61 | $2.60M | 790,321 |
| Sep 1, 2023↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 4,600 | $22.47 | $103.4K | 399,943 |
| Aug 7, 2023↗ | Haley Patrick J. | EVP, Commercial | Sell | 30,553 | $20.67 | $631.5K | 285,467 |
| Aug 7, 2023↗ | Senner Christopher J. | EVP and CFO | Sell | 120,000 | $20.60 | $2.47M | 571,631 |
| Aug 3, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 55,710 | $19.63 | $1.09M | 571,976 |
| Apr 5, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 38,930 | $20.01 | $779.0K | 582,435 |
| Mar 14, 2023↗ | WYSZOMIERSKI JACK L | Director | Sell | 15,300 | $16.61 | $254.1K | 317,467 |
| Mar 3, 2023↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 77,860 | $17.13 | $1.33M | 527,716 |
| Mar 1, 2023↗ | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 82,500 | $17.50 | $1.44M | 351,472 |
| Feb 23, 2023↗ | Garber Alan M | Director | Sell | 40,000 | $17.49 | $699.6K | 31,417 |
| Feb 10, 2023↗ | FELDBAUM CARL B | Director | Sell | 40,000 | $17.78 | $711.2K | 18,701 |
| Feb 8, 2023↗ | Haley Patrick J. | EVP, Commercial | Sell | 25,000 | $17.37 | $434.3K | 254,414 |
| Dec 16, 2022↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 20,000 | $15.88 | $317.6K | 410,958 |
| Dec 1, 2022↗ | POSTE GEORGE | Director | Sell | 40,000 | $16.68 | $667.2K | 193,189 |
| Nov 17, 2022↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 36,000 | $22.73 | $818.3K | 604,822 |
| Sep 14, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 40,000 | $17.94 | $717.6K | 261,591 |
| Jun 1, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 18,812 | $18.21 | $342.6K | 239,818 |
| May 13, 2022↗ | WILLSEY LANCE | Director | Sell | 40,000 | $19.65 | $786.0K | 424,415 |
| Apr 6, 2022↗ | WYSZOMIERSKI JACK L | Director | Sell | 6,696 | $23.00 | $154.0K | 273,192 |
| Apr 4, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 20,000 | $22.72 | $454.3K | 269,191 |
| Mar 30, 2022↗ | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 18,000 | $22.00 | $396.0K | 618,519 |
| Mar 3, 2022↗ | Garber Alan M | Director | Sell | 21,301 | $21.00 | $447.3K | 31,417 |
| Feb 28, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 31,238 | $19.53 | $610.1K | 198,476 |
| Feb 28, 2022↗ | Hessekiel Jeffrey | EVP and General Counsel | Sell | 18,000 | $20.00 | $360.0K | 555,361 |
| Feb 24, 2022↗ | FELDBAUM CARL B | Director | Sell | 20,000 | $19.49 | $389.8K | 8,521 |
| Feb 24, 2022↗ | PAPADOPOULOS STELIOS | Director | Sell | 84,515 | $19.56 | $1.65M | 1,220,040 |
| Feb 4, 2022↗ | Haley Patrick J. | EVP, Commercial | Sell | 60,000 | $17.91 | $1.07M | 245,241 |
| Dec 17, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 47,500 | $17.44 | $828.4K | 363,172 |
| Nov 26, 2021↗ | Haley Patrick J. | EVP, Commercial | Sell | 17,236 | $17.25 | $297.3K | 237,802 |
| Nov 23, 2021↗ | FELDBAUM CARL B | Director | Sell | 20,000 | $17.62 | $352.4K | 8,521 |
| Nov 17, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 47,500 | $18.09 | $859.3K | 411,240 |
| Nov 3, 2021↗ | Hessekiel Jeffrey | EVP and General Counsel | Sell | 5,117 | $22.03 | $112.7K | 632,825 |
| Oct 15, 2021↗ | Hessekiel Jeffrey | EVP and General Counsel | Sell | 12,883 | $22.02 | $283.7K | 637,942 |
| Oct 15, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 47,500 | $21.92 | $1.04M | 411,240 |
| Sep 17, 2021↗ | Haley Patrick J. | EVP, Commercial | Sell | 25,000 | $20.36 | $509.0K | 280,994 |
| Sep 17, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 47,500 | $20.46 | $971.9K | 389,467 |
| Aug 18, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 55,000 | $18.44 | $1.01M | 389,467 |
| Jul 16, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 60,000 | $17.47 | $1.05M | 389,467 |
| Jun 22, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 60,000 | $22.18 | $1.33M | 389,467 |
| May 18, 2021↗ | Haley Patrick J. | EVP, Commercial | Sell | 14,593 | $24.73 | $360.9K | 280,994 |
| May 17, 2021↗ | Freire Maria C | Director | Sell | 8,275 | $25.01 | $207.0K | 31,827 |
| May 17, 2021↗ | MARCHESI VINCENT T | Director | Sell | 40,000 | $25.04 | $1.00M | 66,115 |
| May 17, 2021↗ | POSTE GEORGE | Director | Sell | 40,802 | $24.97 | $1.02M | 157,190 |
| May 14, 2021↗ | Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | Sell | 100,000 | $25.38 | $2.54M | 614,078 |
| May 13, 2021↗ | PAPADOPOULOS STELIOS | Director | Sell | 20,770 | $24.98 | $518.8K | 1,288,130 |
| Apr 28, 2021↗ | Haley Patrick J. | EVP, Commercial | Sell | 7,665 | $25.03 | $191.9K | 297,392 |
| Apr 28, 2021↗ | Hessekiel Jeffrey | EVP and General Counsel | Sell | 18,000 | $25.03 | $450.5K | 628,248 |
| Apr 28, 2021↗ | Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | Sell | 50,000 | $25.00 | $1.25M | 613,482 |
| Apr 2, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 60,000 | $22.96 | $1.38M | 389,467 |
| Apr 2, 2021↗ | Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | Sell | 50,000 | $23.00 | $1.15M | 613,482 |
| Mar 31, 2021↗ | WYSZOMIERSKI JACK L | Director | Sell | 6,220 | $22.64 | $140.8K | 231,589 |
| Mar 17, 2021↗ | Garber Alan M | Director | Sell | 40,000 | $23.60 | $944.0K | 12,718 |
| Mar 3, 2021↗ | Lamb Peter | EVP, Scientific Strategy & CSO | Sell | 65,000 | $22.11 | $1.44M | 340,072 |
EXEL Insiders
Similar Stocks to EXEL
VRTX
Vertex Pharmaceuticals Incorporated
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$42.07B
INSM
Insmed Incorporated
$30.07B
UTHR
United Therapeutics Corporation
$23.50B
MRNA
Moderna, Inc.
$20.76B
ROIV
Roivant Sciences Ltd.
$20.08B
RPRX
Royalty Pharma plc
$19.56B